DSM Pharmaceuticals Appoints Business Unit Director - - BioPharm International

ADVERTISEMENT

DSM Pharmaceuticals Appoints Business Unit Director



DSM Pharmaceuticals has appointed Manja Bouman PhD as president and business unit director of its biopharm businesses at DSM Pharmaceutical Products. Bouman will head the DSM Biologics/BioSolutions businesses within the DSM Pharmaceutical Products business group of Royal DSM. Bouman will report to Lukas Utiger, president and CEO of DSM Pharmaceutical Products, as a member of the management team.

Bouman has a PhD in biochemistry from the State University of New York at Buffalo, School of Medicine & Biomedical Sciences and has held postdoctoral positions there and in Nijmegen, the Netherlands, before joining DSM Gist-Brocades in 1997. In that role, Bouman was responsible for new business development and licensing & technology moving to Kiadis Pharma B.V. as CEO in 2004. Bouman was most recently CEO of Regenesance, a company that focuses on the development of monoclonal antibodies that inhibit MAC formation for treatment of chronic and acute neurological disorders.

Bouman also heads DSM BioSolutions, which offers large-scale fermentation for large-and small-molecule API’s for therapeutic proteins and enzymes at DSM’s Capua, Italy site, with support from the DSM Biotechnology Center in Delft, the Netherlands.

Source: DSM Pharmaceuticals

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines

Click here